1. Show article details.

    Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform

    GlobeNewswire – 9:15 AM ET 02/19/2020

    Meridian Bioscience, Inc. (VIVO) and Exalenz Bioscience Ltd. announced today that the two companies have entered into a definitive agreement for Meridian to acquire Exalenz for ₪6.10 per share in cash with an implied transaction value of approximately $49 million.

  2. Show article details.

    BRIEF-Meridian Bioscience Reports First Quarter Fiscal 2020 Operating Results And Reaffirms 2020 Guidance

    Reuters – 9:06 AM ET 02/07/2020

    Meridian Bioscience Inc (VIVO): * MERIDIAN BIOSCIENCE REPORTS FIRST QUARTER FISCAL 2020 OPERATING RESULTS AND REAFFIRMS 2020 GUIDANCE. * Q1 GAAP EARNINGS PER SHARE $0.07. * Q1 ADJUSTED EARNINGS PER SHARE $0.10. * QTRLY NET REVENUES $47.4 MILLION VERSUS $51.5 MILLION.

  3. Show article details.

    Meridian Bioscience Reports First Quarter Fiscal 2020 Operating Results and Reaffirms 2020 Guidance

    GlobeNewswire – 7:30 AM ET 02/07/2020

    Meridian Bioscience, Inc. (VIVO) today announced financial results for the first quarter ended December 31, 2019.

  4. Show article details.

    Meridian Bioscience Lyo-Ready 1-Step RT-qPCR Mix is Used in the Development of Molecular Diagnostics for New Coronavirus Outbreak

    GlobeNewswire – 9:17 AM ET 01/27/2020

    Meridian Bioscience, Inc. (VIVO) today announced a novel coronavirus, identified by Chinese authorities on January 7 and currently named 2019-nCoV, is a new strain that had not been previously identified in humans.

  5. Show article details.

    Meridian Launched a New High-Fidelity Polymerase to Offer Robust Amplification for NGS and PCR Applications

    GlobeNewswire – 8:00 AM ET 01/23/2020

    Meridian Bioscience, Inc. (VIVO) today announced the launch of a High-Specificity Pfu HS Mix that not only provides high-fidelity amplification, but also offers market-leading amplification for companion diagnostic and clinical testing.

  6. Show article details.

    Meridian Bioscience to Hold First Quarter 2020 Financial Results Conference Call on February 7, 2020

    GlobeNewswire – 4:30 PM ET 01/15/2020

    Meridian Bioscience, Inc. (VIVO), a provider of diagnostic testing solutions and life science raw materials, will report first quarter 2020 financial results Friday, February 7, 2020. Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions.

  7. Show article details.

    Meridian Bioscience Reports Fourth Quarter and Full-Year Fiscal 2019 Operating Results and Provides Fiscal 2020 Guidance

    GlobeNewswire – 7:30 AM ET 11/07/2019

    Meridian Bioscience, Inc. (VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2019. Fourth Quarter 2019 Highlights: Full Fiscal Year 2019 Highlights: Fourth Quarter Fiscal 2019 ResultsConsolidated revenue for the fourth quarter of fiscal 2019 decreased 4% to $50.8 million, compared to $53.1 million last year.

  8. Show article details.

    Meridian submits Curian™ analyzer and the Curian™ HpSA assay to the FDA

    GlobeNewswire – 7:30 AM ET 11/06/2019

    Meridian Bioscience (VIVO), Inc.  today announced that it has submitted Curian™ and the Curian™ HpSA assay to the FDA for review. Recent studies have shown that Helicobacter pylori infections are a major public health concern globally. Lawrence Mertz, Senior Vice President of Research and Development, stated, “We are excited to be the first to develop a rapid fluorescent lateral flow HpSA assay.

  9. Show article details.

    Meridian Bioscience to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on November 7, 2019

    GlobeNewswire – 11:00 AM ET 10/16/2019

    Meridian Bioscience, Inc. (VIVO), a provider of diagnostic testing solutions and life science raw materials will report fourth quarter and full year 2019 financial results Thursday, November 7, 2019.

Page:

Today's and Upcoming Events

  • Apr
    29

    VIVO to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • Feb
    07

    VIVO announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.